Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models

W. Eaton, Jeffrey; A. Menzies, Nicolas; Stover, John; Cambiano, Valentina; Chindelevitch, Leonid; Cori, Anne; A. C. Hontelez, Jan; Humair, Salal; C. Kerr, Cliff; J. Klein, Daniel; Mishra, Sharmistha; M. Mitchell, Kate; E Nichols, Brooke; Vickerman, Peter; Bakker, Roel; Bärnighausen, Till; Bershteyn, Anna; E. Bloom, David; Boily, Marie‐Claude; T. Chang, Stewart; Cohen, Ted; J. Dodd, Peter; Fraser, Christophe; Gopalappa, Chaitra; Lundgren, Jens; K. Martin, Natasha; Mikkelsen, Evelinn; Mountain, Elisa; Duy Pham, Quang; Pickles, Michael; Phillips, Andrew; Platt, Lucy; Pretorius, Carel; Prudden, H; A. Salomon, Joshua; van de Vijver, David; J. de Vlas, Sake; G. Wagner, Bradley; G. White, Richard; P. Wilson, David; Zhang, Lei; M. Blandford, John; Meyer‐Rath, Gesine; Remme, Michelle; Revill, Paul; Sangrujee, Nalinee; Terris‐Prestholt, Fern; Doherty, Meg; Shaffer, Nathan; Easterbrook, Philippa; Hirnschall, Gottfried; B. Hallett, Timothy

doi:10.1016/s2214-109x(13)70172-4

Public

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models

Published in The Lancet Global Health • Dec 9, 2013

Authors:

Jeffrey W. Eaton

Nicolas A. Menzies

John Stover

Abstract

BACKGROUND: New WHO guidelines recommend initiation of antiretroviral therapy for HIV-positive adults with CD4 counts of 500 cells per μL or less, a higher threshold than was previously recommended. Country decision makers have to decide whether to further expand eligibility for antiretroviral thera...

Subject

Antiretroviral therapy

Medicine

Cost–benefit analysis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!